Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-14-144322
Filing Date
2014-04-15
Accepted
2014-04-15 17:03:00
Documents
10
Effectiveness Date
2014-04-15

Document Format Files

Seq Description Document Type Size
1 DEFA14A d710827ddefa14a.htm DEFA14A 30793
2 GRAPHIC g710827g05u79.jpg GRAPHIC 17528
3 GRAPHIC g710827g18f92.jpg GRAPHIC 71936
4 GRAPHIC g710827g31s63.jpg GRAPHIC 21716
5 GRAPHIC g710827g34f65.jpg GRAPHIC 31978
6 GRAPHIC g710827g43j78.jpg GRAPHIC 19563
7 GRAPHIC g710827g46w42.jpg GRAPHIC 42055
8 GRAPHIC g710827g56a18.jpg GRAPHIC 23717
9 GRAPHIC g710827g80c86.jpg GRAPHIC 16020
10 GRAPHIC g710827g97j50.jpg GRAPHIC 18851
  Complete submission text file 0001193125-14-144322.txt   396206
Mailing Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020
Business Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020 720-940-2200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-22873 | Film No.: 14765643
SIC: 2835 In Vitro & In Vivo Diagnostic Substances